Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2018, Article ID 8567905, 14 pages
https://doi.org/10.1155/2018/8567905
Research Article

Decoction of Chinese Herbal Medicine Fuzheng Kang-Ai Induces Lung Cancer Cell Apoptosis via STAT3/Bcl-2/Caspase-3 Pathway

1Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China
2The Postdoctoral Research Station, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China
3Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, Guangdong, China
4Laboratory of Tumor Biology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical Collage, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China

Correspondence should be addressed to Wanyin Wu; moc.621@niynaww and Swei Sunny Hann; moc.kooltuo@2102nnah

Received 21 December 2017; Revised 11 March 2018; Accepted 27 March 2018; Published 25 June 2018

Academic Editor: Min Li

Copyright © 2018 Sumei Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar
  2. W. Chen, R. Zheng, S. Zhang et al., “Report of incidence and mortality in China cancer registries, 2009,” Chinese Journal of Cancer Research, vol. 25, pp. 10–21, 2013. View at Google Scholar
  3. A. Verdecchia, S. Francisci, H. Brenner et al., “Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data,” The Lancet Oncology, vol. 8, no. 9, pp. 784–796, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. X.-J. Zhou, M. Liu, J.-J. Yan, Y. Cao, and P. Liu, “Antidepressant-like effect of the extracted of Kai Xin San, a traditional Chinese herbal prescription, is explained by modulation of the central monoaminergic neurotransmitter system in mouse,” Journal of Ethnopharmacology, vol. 139, no. 2, pp. 422–428, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Han, H. Wang, W. Xu et al., “Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients,” Complementary Therapies in Medicine, vol. 24, pp. 81–89, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. S. J. Shen, Y. H. Zhang, X. X. Gu, S. J. Jiang, and L. J. Xu, “Yangfei Kongliu Formula, a compound Chinese herbal medicine, combined with cisplatin, inhibits growth of lung cancer cells through transforming growth factor-beta1 signaling pathway,” Journal of integrative medicine, vol. 15, pp. 242–251, 2017. View at Google Scholar
  7. J. Mondal, A. Samadder, and A. R. Khuda-Bukhsh, “Psorinum 6× triggers apoptosis signals in human lung cancer cells,” Journal of Integrative Medicine, vol. 14, no. 2, pp. 143–153, 2016. View at Publisher · View at Google Scholar
  8. X.-B. Yang, W.-Y. Wu, S.-Q. Long et al., “Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Study protocol for a randomized controlled trial,” Trials, vol. 16, no. 1, article no. 146, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. W.-Y. Wu, X.-B. Yang, H. Deng et al., “Treatment of advanced non-small cell lung cancer with extracorporeal high frequency thermotherapy combined with Chinese medicine,” Chinese Journal of Integrative Medicine, vol. 16, no. 5, pp. 406–410, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. X.-B. Yang, W.-Y. Wu, S.-Q. Long, H. Deng, and Z.-Q. Pan, “Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study,” Complementary Therapies in Medicine, vol. 22, no. 6, pp. 1010–1018, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Zheng, J. Wu, X. Li et al., “Chinese Herbal Medicine Fuzheng Kang-Ai Decoction Inhibited Lung Cancer Cell Growth through AMPK α -Mediated Induction and Interplay of IGFBP1 and FOXO3a,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 5060757, 15 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Li, S. Wang, F. Zheng, W. Wu, and S. S. Hann, “Chinese herbal medicine Fuzheng Kang-Ai decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt -mediated suppressing MUC1 expression,” Journal of Ethnopharmacology, vol. 194, pp. 918–929, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Xiao and S. V. Singh, “Diallyl trisulfide, a constituent of processed garlic, inactivates Akt to trigger mitochondrial translocation of BAD and caspase-mediated apoptosis in human prostate cancer cells,” Carcinogenesis, vol. 27, no. 3, pp. 533–540, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Wang, J. Yang, L. Chen et al., “Artesunate induces apoptosis through caspase-dependent and -independent mitochondrial pathways in human myelodysplastic syndrome SKM-1 cells,” Chemico-Biological Interactions, vol. 219, pp. 28–36, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Frenzel, F. Grespi, W. Chmelewskij, and A. Villunger, “Bcl2 family proteins in carcinogenesis and the treatment of cancer,” Apoptosis, vol. 14, no. 4, pp. 584–596, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. J. D. Ly, D. R. Grubb, and A. Lawen, “The mitochondrial membrane potential (m) in apoptosis; an update,” Apoptosis, vol. 8, no. 2, pp. 115–128, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. A. G. Porter and R. U. Jänicke, “Emerging roles of caspase-3 in apoptosis,” Cell Death & Differentiation, vol. 6, no. 2, pp. 99–104, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. J. R. Hart, L. Liao, J. R. Yates III, and P. K. Vogt, “Essential role of stat3 in pi3k-induced oncogenic transformation,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 108, no. 32, pp. 13247–13252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. W. You, Q. Tang, C. Zhang et al., “IL-26 Promotes the Proliferation and Survival of Human Gastric Cancer Cells by Regulating the Balance of STAT1 and STAT3 Activation,” PLoS ONE, vol. 8, no. 5, Article ID e63588, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. T. G. Cotter, “Apoptosis and cancer: the genesis of a research field,” Nature Reviews Cancer, vol. 9, no. 7, pp. 501–507, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Pan and F. X. Claret, “Targeting Jab1/CSN5 in nasopharyngeal carcinoma,” Cancer Letters, vol. 326, no. 2, pp. 155–160, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Pan, Q. Zhang, L. Tian et al., “Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma,” Cancer Research, vol. 72, no. 7, pp. 1890–1900, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. X. Chi, J. Kale, B. Leber, and D. W. Andrews, “Regulating cell death at, on, and in membranes,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1843, no. 9, pp. 2100–2113, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Fulda, “Targeting apoptosis for anticancer therapy,” Seminars in Cancer Biology, vol. 31, pp. 84–88, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Cosentino and A. J. García-Sáez, “Mitochondrial alterations in apoptosis,” Chemistry and Physics of Lipids, vol. 181, pp. 62–75, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. S. W. G. Tait and D. R. Green, “Mitochondrial regulation of cell death,” Cold Spring Harbor Perspectives in Biology, vol. 5, no. 9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. D. R. Green and J. C. Reed, “Mitochondria and apoptosis,” Science, vol. 281, no. 5381, pp. 1309–1312, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Ghatan, S. Larner, Y. Kinoshita et al., “p38 MAP kinase mediates Bax translocation in nitric oxide-induced apoptosis in neurons,” The Journal of Cell Biology, vol. 150, no. 2, pp. 335–347, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. P. H. Yin, X. Liu, Y. Y. Qiu et al., “Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: new hope for cancer patients,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 11, pp. 5339–5343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Wang, F. Lafdil, X. Kong, and B. Gao, “Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target,” International Journal of Biological Sciences, vol. 7, no. 5, pp. 536–550, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Tao, G. Huang, R. Wang et al., “Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway,” Scientific Reports, vol. 6, Article ID 38408, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. S. I. Grivennikov and M. Karin, “Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer,” Cytokine & Growth Factor Reviews, vol. 21, no. 1, pp. 11–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. T. J. Shackleford and F. X. Claret, “JAB1/CSN5: A new player in cell cycle control and cancer,” Cell Division, vol. 5, article no. 26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. T. J. Shackleford, Q. Zhang, L. Tian et al., “Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells,” Breast Cancer Research, vol. 13, no. 3, article no. R65, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. C. J. Sherr and J. M. Roberts, “CDK inhibitors: positive and negative regulators of G1-phase progression,” Genes & Development, vol. 13, no. 12, pp. 1501–1512, 1999. View at Publisher · View at Google Scholar · View at Scopus